Mengdie Wang

ORCID: 0000-0002-9206-7063
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Health, Environment, Cognitive Aging
  • Angiogenesis and VEGF in Cancer
  • Delphi Technique in Research
  • Cardiovascular Health and Risk Factors
  • Lymphatic System and Diseases
  • Caveolin-1 and cellular processes
  • Spaceflight effects on biology
  • Cancer, Hypoxia, and Metabolism
  • Cellular Mechanics and Interactions
  • Cancer Cells and Metastasis
  • Air Quality and Health Impacts
  • Hippo pathway signaling and YAP/TAZ
  • Nutritional Studies and Diet
  • Cell Adhesion Molecules Research

China Medical University
2024

Dalian Institute of Chemical Physics
2024

Chinese Academy of Sciences
2024

University of Massachusetts Chan Medical School
2022-2024

Although adverse environmental exposures are considered a major cause of chronic diseases, current studies provide limited information on real-world chemical and related risks. For this study, we collected serum samples from 5696 healthy people patients, including those with 12 in China completed biomonitoring 267 chemicals via gas liquid chromatography-tandem mass spectrometry. Seventy-four highly frequently detected were used for exposure characterization risk analysis. The results show...

10.1038/s41467-024-46595-z article EN cc-by Nature Communications 2024-03-13

Although blocking the binding of vascular endothelial growth factor (VEGF) to neuropilin-2 (NRP2) on tumor cells is a potential strategy treat aggressive carcinomas, lack effective reagents that can be used clinically has hampered this therapy. Here, we describe generation fully humanized, high-affinity monoclonal antibody (aNRP2-10) specifically inhibits VEGF NRP2, conferring antitumor activity without causing toxicity. Using triple-negative breast cancer as model, demonstrated aNRP2-10...

10.1126/scitranslmed.adf1128 article EN Science Translational Medicine 2023-05-03

Prostate cancers are largely unresponsive to immune checkpoint inhibitors (ICIs), and there is strong evidence that programmed death-ligand 1 (PD-L1) expression itself must be inhibited activate antitumor immunity. Here, we report neuropilin-2 (NRP2), which functions as a vascular endothelial growth factor (VEGF) receptor on tumor cells, an attractive target immunity in prostate cancer because VEGF-NRP2 signaling sustains PD-L1 expression. NRP2 depletion increased T cell activation vitro. In...

10.1126/scitranslmed.ade5855 article EN Science Translational Medicine 2023-05-03

Although the immune checkpoint function of PD-L1 has dominated its study, we report that an unanticipated intrinsic in promoting dynamics persistent cell migration. concentrates at rear migrating carcinoma cells where it facilitates retraction, resulting formation PD-L1–containing retraction fibers and migrasomes. promotes by interacting with localizing β4 integrin to enabling this stimulate contractility. This mechanism involves ability maintain polarity lower membrane tension compared...

10.1083/jcb.202108083 article EN cc-by-nc-sa The Journal of Cell Biology 2022-03-28

The high rate of recurrence after radiation therapy in triple-negative breast cancer (TNBC) indicates that novel approaches and targets are needed to enhance radiosensitivity. Here, we report neuropilin-2 (NRP2), a receptor for vascular endothelial growth factor (VEGF) is enriched on sub-populations TNBC cells with stem cell properties, an effective therapeutic target sensitizing radiotherapy. Specifically, VEGF/NRP2 signaling induces nitric oxide synthase 2 (NOS2) transcription by mechanism...

10.1172/jci181368 article EN cc-by Journal of Clinical Investigation 2024-10-01
Coming Soon ...